Sean  Grant net worth and biography

Sean Grant Biography and Net Worth

ean Grant, MBA brings nearly 15 years of multi-disciplinary experience in healthcare and financial services. Mr. Grant joins Vera from CareDx, where he was Vice President of Corporate Strategy and Business Development. During his tenure, he led M&A, venture investments and partnerships across diagnostics, therapeutics, and digital platforms.

Prior to joining CareDx, Mr. Grant served as Vice President in the Investment Banking Healthcare Division at Citigroup. While at Citigroup, he specialized in public and private capital raising as well as M&A, and executed a broad range of transactions for many of the world’s leading life sciences companies including Gilead, Kite Pharma, and CRISPR Therapeutics. Previous to Citigroup, he held finance, strategy and business development roles at Piper Jaffray, Grant Consulting, and ESI Group.

Mr. Grant holds an MBA from the Johns Hopkins Carey School of Business and a BA in Government and International Politics from George Mason University.

What is Sean Grant's net worth?

The estimated net worth of Sean Grant is at least $3.12 million as of April 3rd, 2024. Mr. Grant owns 66,337 shares of Vera Therapeutics stock worth more than $3,124,473 as of November 5th. This net worth estimate does not reflect any other investments that Mr. Grant may own. Additionally, Mr. Grant receives an annual salary of $642,000.00 as CFO at Vera Therapeutics. Learn More about Sean Grant's net worth.

How old is Sean Grant?

Mr. Grant is currently 39 years old. There are 4 older executives and no younger executives at Vera Therapeutics. The oldest executive at Vera Therapeutics is Dr. Robert M. Brenner M.D., Chief Medical Officer, who is 56 years old. Learn More on Sean Grant's age.

What is Sean Grant's salary?

As the CFO of Vera Therapeutics, Inc., Mr. Grant earns $642,000.00 per year. The highest earning executive at Vera Therapeutics is Dr. Marshall W. Fordyce M.D., Founder, President, CEO & Director, who commands a salary of $910,140.00 per year. Learn More on Sean Grant's salary.

How do I contact Sean Grant?

The corporate mailing address for Mr. Grant and other Vera Therapeutics executives is , , . Vera Therapeutics can also be reached via phone at 650-770-0077 and via email at [email protected]. Learn More on Sean Grant's contact information.

Has Sean Grant been buying or selling shares of Vera Therapeutics?

Sean Grant has not been actively trading shares of Vera Therapeutics over the course of the past ninety days. Most recently, Sean Grant sold 99,828 shares of the business's stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a transaction totalling $3,954,187.08. Following the completion of the sale, the chief financial officer now directly owns 66,337 shares of the company's stock, valued at $2,627,608.57. Learn More on Sean Grant's trading history.

Who are Vera Therapeutics' active insiders?

Vera Therapeutics' insider roster includes Marshall Fordyce (Founder), Marshall Fordyce (CEO and Founder), Sean Grant (CFO), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.

Are insiders buying or selling shares of Vera Therapeutics?

In the last year, Vera Therapeutics insiders bought shares 1 times. They purchased a total of 161,290 shares worth more than $4,999,990.00. In the last year, insiders at the sold shares 12 times. They sold a total of 1,680,949 shares worth more than $44,809,507.61. The most recent insider tranaction occured on October, 28th when Director Beth C Seidenberg sold 15,000 shares worth more than $720,450.00. Insiders at Vera Therapeutics own 21.7% of the company. Learn More about insider trades at Vera Therapeutics.

Information on this page was last updated on 10/28/2024.

Sean Grant Insider Trading History at Vera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2024Sell99,828$39.61$3,954,187.0866,337View SEC Filing Icon  
6/23/2023Buy5,000$16.60$83,000.005,992View SEC Filing Icon  
6/15/2022Buy5,000$13.60$68,000.002,816View SEC Filing Icon  
See Full Table

Sean Grant Buying and Selling Activity at Vera Therapeutics

This chart shows Sean Grant's buying and selling at Vera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vera Therapeutics Company Overview

Vera Therapeutics logo
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $47.70
Low: $44.94
High: $48.00

50 Day Range

MA: $40.65
Low: $35.66
High: $47.34

2 Week Range

Now: $47.70
Low: $9.88
High: $50.78

Volume

843,649 shs

Average Volume

910,195 shs

Market Capitalization

$2.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03